Status:
COMPLETED
A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
Lead Sponsor:
Biota Scientific Management Pty Ltd
Conditions:
Rhinovirus
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on * shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold), * ...
Detailed Description
Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for ass...
Eligibility Criteria
Inclusion
- Male and female subjects aged 18-70 years
- Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3
- Presumptive human rhinovirus infection
Exclusion
- Current severe asthma exacerbation
- Severe asthma, GINA steps 4 or higher
- Uncontrolled or clinically significant medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol
- Current smoker, ex-smoker of \<1 year, or history of smoking \>/=10 pack years.
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01175226
Start Date
August 1 2010
End Date
March 1 2012
Last Update
May 31 2018
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Scottsdale, Arizona, United States, 85251
2
Research Site
Little Rock, Arkansas, United States, 72205
3
Research Site
Fountain Valley, California, United States, 92708
4
Research Site
Orange, California, United States, 92868